Pemtumomab
Pemtumomab (trade name Theragyn) is a mouse monoclonal antibody used to treat cancer. The substance has affinity to various types of cancer, like ovarian cancer and peritoneal cancer, via the polymorphic epithelial mucin (PEM or MUC-1) and delivers the radioisotope Yttrium-90 into the tumour.[1] As of 2009, it is undergoing Phase III clinical trials.[2]
Monoclonal antibody | |
---|---|
Type | ? |
Source | Mouse |
Target | MUC1 |
Clinical data | |
Trade names | Theragyn |
Routes of administration | Intraperitoneal |
ATC code |
|
Identifiers | |
ChemSpider |
|
|
It has been granted orphan drug status in Europe.[3]
References
- Oei, AL; Moreno, M; Verheijen, RH; Sweep, FC; Thomas, CM; Massuger, LF; Von Mensdorff-Pouilly, S (2008). "Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer". International Journal of Cancer. 123 (8): 1848–53. doi:10.1002/ijc.23725. PMID 18661524.
- ClinicalTrials.gov
- Antisoma's Lead Product, Pemtumomab Granted European Orphan Drug Status
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.